Dare Bioscience Inc (DARE): Next-Year EPS Estimate 47.02%
As of 2026-09-18, Dare Bioscience Inc (DARE) has a next-year EPS growth estimate of 47.02%. Featured in 2 EPS revision reports, most recently on 2026-04-20.
On 2026-08-18, analyst consensus for DARE's next-year EPS growth shifted from 55.54% to 47.02% — a negative change of 8.52 percentage points. The revised estimate has been sustained across 29 subsequent trading sessions. Current-year growth is projected at 34.72%.
What's Driving This
DARE’s rise is primarily tied to analysts lifting its next-year EPS growth estimate from 55.54% to 47.02% on 2026-08-18, a notable positive revision. No specific headline—such as an earnings beat, contract win, or guidance raise—clearly explains that upgrade; the recent news centers on an at-the-market offering and a Phase 2 HPV trial start. The upward move has continued beyond the initial revision, suggesting sustained sentiment rather than a single disclosed catalyst.
Generated 2026-09-07 from news as of 2026-09-07
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 47.02%
- EPS growth this year
- 34.72%
- EPS next quarter (est)
- -$0.14
- Last price
- $0.78
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-18 | 47.02% | 34.72% | -$0.14 | $0.78 |
| 2026-09-17 | 47.02% | 34.72% | -$0.14 | $0.75 |
| 2026-09-16 | 47.02% | 34.72% | -$0.14 | $0.73 |
| 2026-09-15 | 47.02% | 34.72% | -$0.14 | $0.73 |
| 2026-09-14 | 47.02% | 34.72% | -$0.14 | $0.74 |
| 2026-09-13 | 47.02% | 34.72% | -$0.14 | $0.71 |
| 2026-09-11 | 47.02% | 34.72% | -$0.14 | $0.71 |
| 2026-09-10 | 47.02% | 34.72% | -$0.14 | $0.71 |
| 2026-09-09 | 47.02% | 34.72% | -$0.14 | $0.72 |
| 2026-09-08 | 47.02% | 34.72% | -$0.14 | $0.71 |
| 2026-09-07 | 47.02% | 34.72% | -$0.14 | $0.72 |
| 2026-09-06 | 47.02% | 34.72% | -$0.14 | $0.72 |
| 2026-09-04 | 47.02% | 34.72% | -$0.14 | $0.72 |
| 2026-09-03 | 47.02% | 34.72% | -$0.14 | $0.71 |
| 2026-09-02 | 47.02% | 34.72% | -$0.14 | $0.74 |
| 2026-09-01 | 47.02% | 34.72% | -$0.14 | $0.77 |
| 2026-08-31 | 47.02% | 34.72% | -$0.14 | $0.76 |
| 2026-08-30 | 47.02% | 34.72% | -$0.14 | $0.74 |
| 2026-08-29 | 47.02% | 34.72% | -$0.14 | $0.74 |
| 2026-08-28 | 47.02% | 34.72% | -$0.14 | $0.74 |
| 2026-08-27 | 47.02% | 34.72% | -$0.14 | $0.74 |
| 2026-08-26 | 47.02% | 34.72% | -$0.14 | $0.75 |
| 2026-08-25 | 47.02% | 34.72% | -$0.14 | $0.82 |
| 2026-08-24 | 47.02% | 34.72% | -$0.14 | $0.80 |
| 2026-08-23 | 47.02% | 34.72% | -$0.14 | $0.82 |
| 2026-08-21 | 47.02% | 34.72% | -$0.14 | $0.82 |
| 2026-08-20 | 47.02% | 34.72% | -$0.14 | $0.81 |
| 2026-08-19 | 47.02% | 34.72% | -$0.14 | $0.82 |
| 2026-08-18 | 47.02% | 34.72% | -$0.14 | $0.77 |
| 2026-08-17 | 55.54% | 22.22% | -$0.18 | $0.81 |
Reports Featuring DARE
Recent News
- Dare Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswire
- Dare Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved TherapiesGlobeNewswire
- Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ...GuruFocus.com
- Dare Bioscience Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To ExpectGuruFocus.com
Screen Performance
Aggregate stats across all 2047 tickers our top-EPS-revision screen has flagged over the past 170 days.
- Median return since detection
- +0.3%
- % of tickers in the green
- 51%
- Median return on winners
- +22.2%
- Large revisions captured
- 1736
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Dare Bioscience Inc's next-year EPS growth estimate?▾
As of 2026-09-18, Dare Bioscience Inc (DARE) has a next-year EPS growth estimate of 47.02%, based on analyst consensus.
When was the latest EPS estimate revision for DARE?▾
The most recent revision occurred on 2026-08-18, when analysts adjusted the next-year EPS growth estimate from 55.54% to 47.02%.
What sector and industry does Dare Bioscience Inc belong to?▾
Dare Bioscience Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. DARE appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Dare Bioscience Inc (DARE) appears here because it was detected by our daily top-EPS-revision-performer screen.